sLAG-3 in non-small-cell lung cancer patients’ serum

BACKGROUND: Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed c...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yayi, Wang, Yan, Zhao, Sha, Zhao, Chao, Zhou, Caicun, Hirsch, Fred R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097502/
https://www.ncbi.nlm.nih.gov/pubmed/30147330
http://dx.doi.org/10.2147/OTT.S164178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097502/
https://www.ncbi.nlm.nih.gov/pubmed/30147330
http://dx.doi.org/10.2147/OTT.S164178

Ejemplares similares